ARG1 and neoplasm: Tumor lysate of the triple therapy also exhibited 5.6 time higher expression of iNOS (N1 marker) and 33% lower expression of Arg1 (N2 marker) than those of the IRE + αPD1 group, respectively (Figure 6A).